Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
The majority of treatment options for cancers are ineffective due to limited therapeutic targeting. Here, the authors develop bispecific antibodies that effectively target nanomaterials to triple-negative breast cancer cell receptors and deliver therapeutics leading to inhibition of tumour growth.
Main Authors: | Yu-Cheng Su, Pierre-Alain Burnouf, Kuo-Hsiang Chuang, Bing-Mae Chen, Tian-Lu Cheng, Steve R. Roffler |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms15507 |
Similar Items
-
Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)
by: Huei-Jen Chen, et al.
Published: (2023-10-01) -
Pseudo-anaphylaxis to PEGylated nanomedicines in a porcine model
by: Janos Szebeni, et al.
Published: (2020-08-01) -
Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
by: Yi-An Cheng, et al.
Published: (2020-08-01) -
Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation
by: Burnouf T, et al.
Published: (2019-11-01) -
PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies
by: Yaelle Bavli, et al.
Published: (2020-01-01)